

Applicants : Ron S. Israeli, et al.
U.S. Serial No.: 08/403,803
Filed : March 17, 1995
Page 2

pursue the subject matter of the cancelled claim in a later filed continuation or divisional application.

Please amend claims 59, 77, 79, and 84 by adding the underlined material and deleting the bracketed material as follows:

- 59. (Amended) A method of suppressing or modulating metastatic ability of prostate tumor cells, prostate tumor growth or elimination of prostate tumor cells, comprising introducing a DNA molecule of claim 2 [encoding a prostate specific membrane antigen] operatively linked to a 5' regulatory element coupled with a therapeutic DNA into a tumor cell of a subject, thereby suppressing or modulating metastatic ability of prostate tumor cells, prostate tumor growth or elimination of prostate tumor cells.--
- 77. (Amended) A therapeutic vaccine for preventing human prostate tumor growth or stimulation of prostate tumor cells in a subject, comprising administering to the subject an effective amount of the cells of claim 74, which expresses or is capable of expressing a prostate specific membrane antigen, and a pharmaceutical acceptable carrier, thereby preventing the tumor growth or stimulation of tumor cells in the subject.--
- 79. The method of claim [78] 90, wherein the primers are derived from a nucleic acid molecule encoding a prostate specific membrane antigen.--
- 84. (Amended) A method of abrogating mitogenic response due to transferrin, comprising introducing a DNA molecule of claim 2 [encoding prostate specific membrane antigen] operatively linked to a 5' regulatory element into a tumor cell, the expression

Applicants : Ron S. Israeli, et al.
U.S. Serial No.: 08/403,803
Filed : March 17, 1995
Page 3

of which gene is directly associated with a defined pathological effect within a multicellular organism, thereby abrogating mitogen response due to transferrin.--

Please add new claims 90-92 as follows:

- 90. (New) A method of detecting micrometastatic tumor cells of a subject, comprising performing polymerase chain reaction (PCR) on tissue, blood fluid, or cells of the subject using primers that hybridize with the nucleic acid molecule of claim 1, thereby detecting micrometastatic tumor cells of the subject.--
- 91. (New) A method of detecting a nucleic acid molecule encoding a prostate specific membrane antigen comprising performing polymerase chain reaction (PCR) on a mammalian tissue or cell using primers that hybridize with the nucleic acid molecule of claim 1, thereby detecting a nucleic acid molecule encoding a prostate specific membrane antigen.--
- 92. (New) The method of claim 1, wherein the nucleic acid molecule is DNA, RNA or cDNA.--

REMARKS

The subject application is a continuation application of U.S. Serial No. 08/403,803, filed March 17, 1995, and a continuation of PCT International Application No. PCT/US93/10624, filed November 5, 1993; which is a continuation-in-part of U.S. Serial 07/973,337, filed November 5, 1992.

The parent application U.S. Serial No. 08/403,803, filed March 17, 1995 is still pending. Thus, the parent application is